Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 5 | 9 |
| List of Tables | 8 | 4 |
| List of Figures | 12 | 2 |
| Adult and Adolescent Vaccines Market to 2018 - Introduction | 14 | 1 |
| Overview | 14 | 1 |
| Adult and Adolescent Vaccines Market to 2018 - Overview | 15 | 10 |
| Vaccine Preventable Diseases | 15 | 1 |
| Types of Vaccines | 16 | 1 |
| Recommendations for Immunization | 17 | 1 |
| The US | 17 | 2 |
| Top Five European Countries | 19 | 1 |
| Japan | 20 | 1 |
| Regulatory Framework | 21 | 1 |
| The US | 21 | 1 |
| Top Five European Countries | 22 | 1 |
| The UK | 22 | 1 |
| France | 22 | 1 |
| Germany | 22 | 1 |
| Italy | 23 | 1 |
| Spain | 23 | 1 |
| Japan | 23 | 1 |
| Vaccine Manufacturing Process | 24 | 1 |
| Adult and Adolescent Vaccines Market to 2018 - Market Characterization and Forecast | 25 | 6 |
| Revenue Forecast | 25 | 2 |
| Market Share by Type of Vaccines | 27 | 1 |
| Market Share by Geography | 28 | 1 |
| Drivers | 28 | 1 |
| Adult Vaccines Segment to Drive Future Growth | 28 | 1 |
| High Unmet Needs | 28 | 1 |
| Targeting New Diseases Areas for Vaccines Likely To Drive the Market | 29 | 1 |
| Novel Vaccine Technologies | 29 | 1 |
| Restraints | 30 | 1 |
| Production Capacity Limitations | 30 | 1 |
| High Initial Capital Investments and Technical Expertise | 30 | 1 |
| Regulations Delay Vaccine Launch and Acceptance | 30 | 1 |
| Adult and Adolescent Vaccines Market to 2018 - Influenza Vaccines | 31 | 11 |
| Disease Overview | 31 | 1 |
| Market Forecasts | 32 | 1 |
| The US | 32 | 2 |
| Top Five European Countries | 34 | 2 |
| Japan | 36 | 1 |
| Cost of Vaccination | 37 | 1 |
| The US | 37 | 1 |
| Top Five European Countries | 37 | 1 |
| Japan | 38 | 1 |
| Pipeline Analysis - Influenza Vaccines | 39 | 3 |
| Adult and Adolescent Vaccines Market to 2018 - Tetanus, Diphtheria and Pertussis Vaccines | 42 | 8 |
| Disease Overview | 42 | 1 |
| Market Forecasts | 43 | 1 |
| The US | 43 | 1 |
| Top Five European Countries | 44 | 2 |
| Japan | 46 | 1 |
| Cost of Vaccination | 47 | 1 |
| The US | 47 | 1 |
| Top Five European Countries | 47 | 1 |
| Japan | 48 | 1 |
| Pipeline Analysis - Tetanus, Diphtheria, Pertussis (Td/Tdap) Vaccines | 49 | 1 |
| Adult and Adolescent Vaccines Market to 2018 - Pneumococcal Vaccines | 50 | 10 |
| Disease Overview | 50 | 1 |
| Market Forecasts | 51 | 1 |
| The US | 51 | 1 |
| Prevnar 13 | 52 | 1 |
| Efficacy | 52 | 1 |
| Safety | 52 | 1 |
| Clinical Study Details | 52 | 1 |
| Top Five European Countries | 53 | 2 |
| Japan | 55 | 1 |
| Cost of Vaccination | 56 | 1 |
| The US | 56 | 1 |
| Top Five European Countries | 56 | 1 |
| Japan | 57 | 1 |
| Pipeline Analysis - Pneumococcal Vaccines | 58 | 2 |
| Adult and Adolescent Vaccines Market to 2018 - Meningococcal Vaccines | 60 | 6 |
| Disease Overview | 60 | 1 |
| Market Forecasts | 61 | 1 |
| The US | 61 | 1 |
| Top Five European Countries | 62 | 2 |
| Cost of Vaccination | 64 | 1 |
| The US | 64 | 1 |
| Top Five European Countries | 64 | 1 |
| Pipeline Analysis - Meningococcal Vaccines | 65 | 1 |
| Adult and Adolescent Vaccines Market to 2018 - Human Papilloma Virus Vaccines | 66 | 9 |
| Disease Overview | 66 | 1 |
| Market Forecasts | 67 | 1 |
| The US | 67 | 1 |
| Top Five European Countries | 68 | 2 |
| Japan | 70 | 1 |
| Cost of Vaccination | 71 | 1 |
| The US | 71 | 1 |
| Top Five European Countries | 71 | 1 |
| Japan | 72 | 1 |
| Pipeline Analysis - Human Papillomavirus Vaccines | 73 | 2 |
| Adult and Adolescent Vaccines Market to 2018 - Hepatitis Vaccines | 75 | 10 |
| Disease Overview | 75 | 1 |
| Market Forecasts | 76 | 1 |
| The US | 76 | 1 |
| Top Five European Countries | 77 | 2 |
| Japan | 79 | 1 |
| Cost of Vaccination | 80 | 1 |
| The US | 80 | 1 |
| Top Five European Countries | 80 | 1 |
| Japan | 81 | 1 |
| Pipeline Analysis - Hepatitis Vaccines | 82 | 3 |
| Adult and Adolescent Vaccines Market to 2018 - Measles, Mumps and Rubella Vaccines | 85 | 5 |
| Disease Overview | 85 | 1 |
| Market Forecasts | 85 | 1 |
| The US | 85 | 2 |
| Top Five European Countries | 87 | 1 |
| Cost of Vaccination | 88 | 1 |
| The US | 88 | 1 |
| Top Five European Countries | 89 | 1 |
| Adult and Adolescent Vaccines Market to 2018 - Zoster Vaccines | 90 | 3 |
| Disease Overview | 90 | 1 |
| Market Forecasts | 90 | 1 |
| The US | 90 | 1 |
| The UK | 91 | 1 |
| Cost of Vaccination | 91 | 1 |
| The US | 91 | 1 |
| The UK | 92 | 1 |
| Pipeline Analysis - Zoster Vaccines | 92 | 1 |
| Adult and Adolescent Vaccines Market to 2018 - Varicella Vaccines | 93 | 6 |
| Disease Overview | 93 | 1 |
| Market Forecasts | 93 | 1 |
| The US | 93 | 1 |
| Top Five European Countries | 94 | 2 |
| Japan | 96 | 1 |
| Cost of Vaccination | 97 | 1 |
| The US | 97 | 1 |
| Top Five European Countries | 97 | 1 |
| Japan | 98 | 1 |
| Pipeline Analysis - Varicella Vaccines | 98 | 1 |
| Adult and Adolescent Vaccines Market to 2018 - Competitive Landscape | 99 | 6 |
| Introduction | 99 | 1 |
| Major Company Profiles | 99 | 1 |
| GlaxoSmithKline | 99 | 1 |
| SWOT Analysis | 100 | 1 |
| Sanofi | 101 | 1 |
| SWOT Analysis | 101 | 1 |
| Pfizer | 102 | 1 |
| SWOT Analysis | 102 | 1 |
| Merck | 103 | 1 |
| SWOT Analysis | 103 | 1 |
| Novartis | 104 | 1 |
| SWOT Analysis | 104 | 1 |
| Adult and Adolescent Vaccines Market to 2018 - Strategic Consolidations | 105 | 8 |
| Deals by Year | 105 | 1 |
| Deals by Type | 106 | 1 |
| Deals by Value | 107 | 1 |
| Deals by Geography | 108 | 1 |
| Summary of Major M&A Deals | 109 | 1 |
| Pfizer Completes Acquisition of Wyeth | 109 | 1 |
| Abbott Labs Acquires Solvay Pharma | 109 | 1 |
| Johnson &Johnson Acquires Crucell | 109 | 1 |
| Amgen Completes the Acquisition of BioVex | 110 | 1 |
| Merck &Co Completes Merger with Schering-Plough | 110 | 1 |
| Summary of Major Licensing Deals | 110 | 1 |
| Immune Design Enters into Licensing Agreement with MedImmune | 110 | 1 |
| Syntiron Enters into Licensing Agreement with Sanofi Pasteur | 110 | 1 |
| Pfenex Enters into Licensing Agreement with Merck | 111 | 1 |
| Summary of Major Partnerships | 111 | 1 |
| GlaxoSmithKline Enters into Co-development Agreement with Intercell | 111 | 1 |
| Merck Enters into Joint Venture with The Wellcome Trust | 111 | 1 |
| GlaxoSmithKline Forms Joint Venture with Jiangsu Walvax | 111 | 1 |
| GenVec Enters into an Agreement with SAIC-Frederick | 112 | 1 |
| Novavax Forms a Joint Venture Company with Cadila Pharma | 112 | 1 |
| Adult and Adolescent Vaccines Market to 2018 - Appendix | 113 | 7 |
| Market Definitions | 113 | 1 |
| Abbreviations | 113 | 2 |
| Bibliography | 115 | 1 |
| Research Methodology | 115 | 4 |
| Coverage | 115 | 1 |
| Secondary Research | 116 | 1 |
| Primary Research | 116 | 1 |
| Model for Estimation of Vaccine Market | 117 | 2 |
| Geographical Landscape | 119 | 1 |
| Pipeline Analysis | 119 | 1 |
| Competitive Landscape | 119 | 1 |
| Expert Panel Validation | 119 | 1 |
| Contact Us | 119 | 1 |
| Disclaimer | 119 | 1 |